{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:19:26Z","timestamp":1792210766633,"version":"4.4.0"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["FONDECYT 1191145 to MA"],"award-info":[{"award-number":["FONDECYT 1191145 to MA"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["FONDECYT 1200227 to JPA"],"award-info":[{"award-number":["FONDECYT 1200227 to JPA"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["FONDECYT 1241450 to MA"],"award-info":[{"award-number":["FONDECYT 1241450 to MA"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec><jats:title>Introduction:<\/jats:title><jats:p> Infections in patients with cirrhosis are associated with high morbidity and mortality. Rifaximin is an antibiotic used to treat and prevent hepatic encephalopathy (HE); however, it has been suggested that it may play a crucial role in reducing infections in these populations. <\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p> To evaluate the role of rifaximin in preventing frequent cirrhosis-related infections [spontaneous bacterial peritonitis, pneumonia, urinary tract infection (UTI), and bacteremia], Clostridioides difficile infection, and all-cause mortality, as well as determining adverse effects and adherence to the drug. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> A retrospective cohort study was conducted on decompensated cirrhotic patients with history of HE between January 2017 and November 2022 at a university center. Patients with cirrhosis, regardless of their etiology and severity, were included in the study, encompassing both hospitalized and outpatient cases. The statistical analysis included adjusted general linear models, Poisson regressions, and propensity score matching. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> We included 153 patients. The mean age in the cohort was 60.2\u2009\u00b1\u200912.3\u2009years and 67 (43.8%) were women. The main cause of cirrhosis was metabolic dysfunction-associated steatotic liver disease 52 (38%), and the median Model of End-Stage Liver Disease sodium was 16.5 (7\u201332). In the cohort, 65 (45%) patients used rifaximin. The mean follow-up was 32\u2009months. Eighty-five patients with infectious events were recorded, and a total of 164 infectious events were registered. The main infectious events were UTIs (62, 37.8%) and pneumonia (38, 23.2%). The use of rifaximin was associated with lower infection rates, displaying an incidence rate ratio (IRR) of 0.64 [95% confidence interval (CI) (0.47\u20130.89); p\u2009=\u20090.008]. However, no discernible impact on mortality outcome was observed [IRR 1.9, 95% CI (0.9\u20134.0); p\u2009=\u20090.09]. There were no reported adverse effects, and no patient discontinued the therapy due to adverse effects. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> The use of rifaximin significantly reduces infections in patients with cirrhosis and HE. Despite rifaximin was associated with a decreased all-cause mortality, this impact was not statistically significant in the adjusted analysis. <\/jats:p><\/jats:sec>","DOI":"10.1177\/17562848241254267","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T11:19:35Z","timestamp":1716808775000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy"],"prefix":"10.1177","volume":"17","author":[{"given":"Francisco","family":"Idalsoaga","sequence":"first","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Robles","sequence":"additional","affiliation":[{"name":"Departamento de Medicina Interna, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Departamento de Medicina Interna, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Corsi","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Fuentes-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias de la Salud, Facultad de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Ayares","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-396X","authenticated-orcid":false,"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Schulich School of Medicine, Western University and London Health Sciences Centre, University Hospital, 339 Windermere Road, Room A10-224, London, ON N6A 5A5, Canada"},{"name":"Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"bibr1-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60121-5"},{"key":"bibr2-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2023.01.006"},{"key":"bibr3-17562848241254267","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i10.2542"},{"key":"bibr4-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.005"},{"key":"bibr5-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.314"},{"key":"bibr6-17562848241254267","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0329"},{"key":"bibr7-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2021808"},{"key":"bibr8-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.282.6272.1262"},{"key":"bibr9-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-10004-1"},{"key":"bibr10-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.027"},{"key":"bibr11-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100719"},{"key":"bibr12-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31708"},{"key":"bibr13-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2015.08.003"},{"key":"bibr14-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893"},{"key":"bibr15-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267647"},{"key":"bibr16-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15326"},{"key":"bibr17-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05804-2"},{"key":"bibr18-17562848241254267","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i2.199"},{"key":"bibr19-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10117-y"},{"key":"bibr20-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221100537"},{"key":"bibr21-17562848241254267","unstructured":"National Institute on Alcohol Abuse and Alcoholism (NIAAA). Drinking levels defined [Internet], https:\/\/www.niaaa.nih.gov\/alcohol-health\/overview-alcohol-consumption\/moderate-binge-drinking (2023, accessed 6 August 2021)."},{"key":"bibr22-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210"},{"key":"bibr23-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25947"},{"key":"bibr24-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp031807"},{"key":"bibr25-17562848241254267","first-page":"1151","volume":"21","author":"Mariani M","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"bibr26-17562848241254267","doi-asserted-by":"publisher","DOI":"10.2174\/1389450119666180924145156"},{"key":"bibr27-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182506dbb"},{"key":"bibr28-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14361"},{"key":"bibr29-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000724"},{"key":"bibr30-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15207"},{"key":"bibr31-17562848241254267","doi-asserted-by":"publisher","DOI":"10.1177\/20503121221090472"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848241254267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848241254267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848241254267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:25:58Z","timestamp":1740803158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848241254267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"alternative-id":["10.1177\/17562848241254267"],"URL":"https:\/\/doi.org\/10.1177\/17562848241254267","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17562848241254267"}}